Focused on Transforming Cancer Therapies

Explore our broad clinical development program

Explore Clinical Trials Right arrow

Explore Clinical Trials

Our pipeline includes the Exelixis-discovered compounds, cabozantinib and zanzalintinib, as well as other programs that are the subject of partnerships and collaborations with several biopharmaceutical companies. The safety and efficacy of these investigational compounds and/or investigational uses of approved products have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any compound or product for unapproved uses.


Molecular structures below are artistic renderings.

{{ product_data.name_display }}

{{ product_data.description }}

View trials

View trials for all compounds

Filter Trials by

Clear Filters
Selected /
{{ product }}
Cancer Type
Selected /
{{ upper(oncology_area) }}
Key Program
Selected /
{{ upper(keyprogram) }}
Trial phase
Selected /
Phase {{ phase }}
View trials
({{ matches }} matches)
Search Icon
Filter Trials by
Search Icon
No trials found with that criteria.

{{ upper(group.oncology_area) }}

Phase {{ trial.phase}}

{{ trial.tumour_type}}

{{ trial.study_number}}
{{ trial.treatment_arms_card}}

{{ trial.status }}

Orange arrow
Back to Top
Orange arrow Back to Clinical Trials

{{ activeTrial.study_number }}

{{ activeTrial.short_title }}

{{ }}

{{ activeProduct.description }}

Phase {{ activeTrial.phase}}

{{ activeTrial.status }}

Tumor Type

{{ activeTrial.tumour_type }}


{{ activeTrial.sponsor }}


Treatment arms

Key eligibility criteria

Dose expansion cohorts

Primary endpoints

NCT identifier

Close Icon
{{ }}
{{ child_item.abbreviation }} , {{ child_item.definition }}
Search Icon
Please adjust your device orientation to portrait mode.